UNSPSC 51111726: Ambazone

This classification denotes an antineoplastic antibiotic with the molecular formula C8H11N7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BYK4592A3Q, chemically known as 1,4-benzoquinone guanylhydrazone thiosemicarbazone but generally known as ambazone, which bears US NIH Compound Identifier 1549158. European Medicines Agency schedules Ambazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12841MIG.

UNSPSC 51111726 Ambazone, a Commodity code, describes pharmaceutical and medical products that state and local governments procure for emergency response, community health, and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for emergency medical response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing networks, and medical and first aid supplies for fire rescue operations. The issuing bodies span county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances — a mixed portfolio of health and safety-focused public entities sourcing products both directly and through authorized wholesale distribution channels.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, targeting quarterly deliveries to the county's community health building with all shipping costs included in bids. The City of Tampa issued ITB 26P00145 on March 25, 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division due March 13, 2026, with an estimated contract value of $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors to supply through three authorized wholesalers effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 as a preliminary market intelligence solicitation regarding direct-to-manufacturer prescription programs for self-insured state health plans. Activity centers in Florida, Texas, and the Midwest multistate region.